Friday, 8 June 2018 |
7:15 am - 8:15 am |
Surefire Hands-On Breakfast Symposium |
7:30 am - 8:45 am |
Machine Learning in Interventional Oncology Moderators: Julius Chapiro, MD, PhD and David C. Madoff, MD
7:30 am - 7:45 am |
Nuts and Bolts of Machine Learning in Interventional Oncology
Aaron Abajian, MD, MS |
7:45 am - 8:00 am |
Big Data and Clinical Outcomes Registries: AI-Based Concepts to Improve Clinical Decision Making in IO
Mark Michalski, MD |
8:00 am - 8:15 am |
The Role of AI in Intraprocedural Imaging and Image Guidance
Raul Uppot, MD |
8:15 am - 8:25 am |
Infrastructure for Machine Learning Research
Brian Letzen, MD, MS |
8:25 am - 8:45 am |
Panel Discussion
Aaron Abajian, MD, MS; Mark Michalski, MD; Raul Uppot, MD; Brian Letzen, MD, MS; and Lynn Savic, MD |
|
7:30 am - 8:45 am |
Scientific Abstract Presentations: Liver IO Moderators: Ping Liang, MD and Suvranu Ganguli, MD
7:30 am - 7:39 am |
Paper 2: Safety and Feasibility of Integrating Yttrium-90 Radioembolization with Capecitabine-Temozolomide for Grade 2 Liver-Dominant Metastatic Neuroendocrine Tumors (CapTemY90): Final Report
TBD |
7:39 am - 7:48 am |
Paper 3: Study of Mobilizable 125I See Chain Coaxial Drainage Catheter Placement for INtraluminal Brachytherapy of Malignant Obstructive Jaundice
TBD |
7:48 am - 7:57 am |
Paper 4: Inflammation Marker as a Biomarker for Overall Survival After Transarterial Chemoemboliztaion: IMportance of Neutrophil-to-Lymphocyte Ratio in Hepatocellular Carcinoma
TBD |
7:57 am - 8:06 am |
Paper 5: Multicentric Assessment of the Hong Kong Liver Cancer Staging System in Chinese Patients Following Transarterial Chemoembolization as Initial Treatment
TBD |
8:06 am - 8:15 am |
Paper 6: Early Safety From a Phase 1 Multicenter Open-Label Clinical Trial of Talimogene Laherparepvec INjected Into Liver Tumors
TBD |
8:15 am - 8:24 am |
Paper 7: Outcomes After Transarterial Embolization Versus Radioembolization of Neuroendocrine Tumor Liver Metastases
TBD |
8:24 am - 8:33 am |
Paper 8: Chonic Hepatic Changes in Patients with Metastatic Neuroendocrine Tumors Treated with Y90 Radioembolization: A Single-Center Experience
TBD |
8:33 am - 8:42 am |
Paper 9: The effect of TACE/Ablation to the Change of TAA Specific T-Cell Response in Hepatocellular Carcinoma
TBD |
|
8:45 am - 9:00 am |
Break & Exhibits |
9:00 am - 10:30 am |
Latest Advances in Lung Tumor Therapy Moderator: Stephen Solomon, MD and Jean Palussière, MD
9:00 am - 9:12 am |
Lung Ablation: Lessons from the Lab
Christopher Brace, MD |
9:12 am - 9:24 am |
Evidence for Treating Oligometastatic Lung Metastases
Michael Lanuti, MD |
9:24 am - 9:36 am |
Ablative Therapy for Lung Metastases
Matthew Callstrom, MD, PhD |
9:36 am - 9:48 am |
Ablative Therapy for Primary Lung Cancer
Jean Palussière, MD |
9:48 am - 10:00 am |
Proton Therapy vs. SBRT in Lung Cancer
Henning Willers, MD |
10:00 am - 10:12 am |
Targeted Therapy and Immunotherapy for Lung Cancer
Christopher G. Azzoli, MD |
10:12 am - 10:24 am |
Imaging After Therapy: Ablation, Radiation, and Systemic Therapies
Robert Suh, MD |
|
|
Hands-On Workshop: Ablation
Moderator: Fred Lee, MD
Panelists: Hyunchul Rhim, MD; Luigi Solbiati, MD; Grant Schmit, MD; Pei Hong Wu, MD |
10:30 am - 11:15 am |
Break & Exhibits |
11:15 am - 12:15 pm |
Immuno-Oncology: What's on the Horizon? Moderator: S. Nahum Goldberg, MD
11:15 am - 11:30 am |
TAEVax: Immunobiologic Treatment Effects of Embolization in a Rat HCC Model
Stephen Hunt, MD, PhD |
11:30 am - 11:45 am |
A Pilot Study of Cryoablation Combined with Immune Checkpoint Inhibitor Therapy in Patients with PD-1 Refractory Metastatic Melanoma: Prospective Clinical Research and Correlative Laboratory Studies
Florian J. Fintelmann, MD |
11:45 am - 12:00 pm |
Investigating the Immunobiology of Hepatocellular Carcinoma in Patients Undergoing Y90 Radioembolization
Rafael Duran, MD |
12:00 pm - 12:15 pm |
T-Cell Clonality and Cancer Neoantigen Presentation Following Interventional Oncology (IO) Therapies: Which IO Techniques Optimally Stimulate the Immune System?
Joseph P. Erinjeri, MD, PhD |
|
12:15 pm - 12:30 pm |
Break & Exhibits |
12:30 pm - 1:10 pm |
Lunch Symposium Presented by BTG
Y90: Moving Beyond a Palliative Approach
|
1:15 pm - 1:55 pm |
Lunch Symposium Presented by Perseon Moderator: Sohail Contractor, MD
1:15 pm - 1:35 pm |
New MTX 915 Mhz Antenna Graded Technology Platform
Dragan D. Nebrigic |
1:35 pm - 1:55 pm |
Perseon Microwave System: Why, When, Where?
Damian Dupuy, MD |
|
2:00 pm - 3:00 pm |
Management of Extrahepatic Biliary Tract Cancer in 2018 Moderators: William Rilling, MD and Timothy Pawlik, MD
2:00 pm - 2:12 pm |
Imaging of Cholangiocarcinoma: The Essentials and Beyond
Ihab Kamel, MD |
2:12 pm - 2:24 pm |
Role of Biliary Drainage and Complex Interventions
Dong Il Gwon, MD |
2:24 pm - 2:36 pm |
Current Surgical Strategies
Timothy Pawlik, MD |
2:36 pm - 2:48 pm |
Systemic Therapies and Clinical Trials
Milind Javle, MD |
2:48 pm - 3:00 pm |
Q&A
All Faculty |
|
|
Case-Based Workshop: Transarterial
Moderator: Hooman Yarmohammadi, MD
Panelists: Kyungmouk Steve Lee, MD; Bora Peynircioglu, MD; Robert Lewandowski, MD |
3:00 pm - 3:15 pm |
Break & Exhibits |
3:15 pm - 4:15 pm |
SIO Meets NANETS: Advances and Controversies in NET Management Moderators: Michael C. Soulen, MD and Thierry de Baere, MD
3:15 pm - 3:25 pm |
Recent Advances in Systemic Therapies for NETs
Jennifer Ang Chan, MD |
3:25 pm - 3:35 pm |
Embolization Should Remain 1st-Line Therapy for Liver-Dominant NET Metastases
Thierry de Baere, MD |
3:35 pm - 3:45 pm |
PRRT Should Become 1st-Line Therapy for Liver-Dominant NET Metastases
Lisa Bodei, MD |
3:45 pm - 3:55 pm |
TARE Should Remain 1st-Line Embolotherapy for Liver-Dominant NET Metastases
Matthew Johnson, MD |
3:55 pm - 4:05 pm |
TARE Causes Long-Term Toxicity and Should be Reserved for 2nd-Line
Michael C. Soulen, MD |
4:05 pm - 4:15 pm |
The New Frontier: Intra-Arterial PRRT
Marnix Lam, MD |
|
|
Palliative Care for the Cancer Patient Moderators: Jennifer Temel, MD and Eric Hohenwalter, MD
3:15 pm - 3:25 pm |
Facilitating Prognostic Awareness in Patients with Advanced Cancer
Jennifer Temel, MD |
3:25 pm - 3:35 pm |
Where Can Interventional Oncology Impact Palliation of Cancer Patients?
Camilla Zimmerman, MD |
3:35 pm - 3:45 pm |
Interventional Supportive Care Therapies in Cancer Patients
Mihir Kamdar, MD |
3:45 pm - 3:550 pm |
Supportive Care Therapies in Oncology
Hooman Yarmohammadi, MD |
3:55 pm - 4:05 pm |
Musculoskeletal and Spine Tumor Interventions
Anil "Nick" Kurup, MD |
4:05 pm - 4:15 pm |
Palliative Embolization
Eric Hohenwalter, MD |
|
4:15 pm - 5:00 pm |
Break & Exhibits |
5:00 pm - 6:15 pm |
Hepatocellular Carcinoma Tumor Board
Moderators: Luigi Solbiati, MD and Matthew Johnson, MD
Panelists: Robert Lewandowski, MD; Dong Il Gwon, MD; Robert Brown, MD; Timothy Pawlik, MD; Yasuaki Arai, MD; Pei Hong Wu, MD; Andrew Zhu, MD
|
6:15 pm - 7:15 pm |
Founding SIO Member Special Event - By Invitation Only |
6:30 pm - 8:15 pm |
IO Essentials, Part II: Practice Development Moderators: Janice Newsome, MD and Kathy Krol, MD
6:30 pm - 6:45 pm |
Building an Academic IO Practice
William Rilling, MD |
6:45 pm - 7:00 pm |
Building a Private IO Practice
Aneesa Majid, MD |
7:00 pm - 7:15 pm |
Opening a Stand Alone Outpatient IO Center
David Sperling, MD |
7:15 pm - 7:35 pm |
Demonstrating the Value of a Clinical Practice To Your Partners
Janice Newsome, MD |
7:35 pm - 8:00 pm |
Demonstrating the Value of IO to Referring Providers
Muneeb Ahmed, MD |
8:00 pm - 8:15 pm |
Documentation: Billing, Coding, E&M
Ray Liu, MD |
|